You may also see it written as BPC-157 or referred to more broadly as a healing peptide
BPC-157 is a 15-residue, 1419.53 g/mol pentadecapeptide whose mechanistic literature centres on local angiogenic signalling, Hsieh and colleagues (J Mol Med, 2017) reported upregulation and internalisation of VEGFR2 in human endothelial cells, and Chang and colleagues (J Appl Physiol, 2011) reported increased FAK and paxillin phosphorylation with greater outgrowth and migration in cultured rat tendon fibroblasts
Objective: An epidemiological survey of hospitalizations for diabetes in the South and Southeast regions of Brazil between 2012 and 2024
BPC-157 consists of 15 amino acids and has been studied for its potential therapeutic effects, particularly in promoting tissue healing and reducing inflammation
For the full BPC-157 dosing breakdown, see our BPC-157 dosage protocol guide: BPC-157: 200 to 500 mcg per day, subcutaneous injection near the injury site, 4 to 8 weeks TB-500 loading phase (Weeks 1-4): 2 to 5 mg twice per week TB-500 maintenance phase (Weeks 5-8): 2 mg once per week Route: Both peptides are administered via subcutaneous injection
In the world of targeted body contouring and metabolic support, AOD-9604 represents a breakthrough approach to stubborn fat reduction